ROSIGLITAZONE-BASED THERAPY REDUCES INFLAMMATORY BIOMARKERS IN DIABETIC, HYPERTENSIVE PATIENTS COMPARED TO A METFORMIN AND GLYBURIDE BASED-REGIMEN: THE ROSITEL RANDOMIZED TRIAL Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

publication date

  • October 1, 2010